291 Corona vaccines under development worldwide

When it comes to corona vaccines, the status quo is just the beginning: even though four vaccines to protect against COVID-19 are already available in this country, intensive research is underway for more worldwide.

According to the World Health Organization (WHO), 291 vaccine candidates are currently in development with vaccines from AstraZeneca, BioNTech/Pfizer, Janssen (Johnson & Johnson) and Moderna.

291 Corona vaccines currently undergoing intensive testing
Of these 291, 107 are already being tested in the clinical phase and thus involving test subjects, while 184 are still in the preclinical testing phase.

As far as the WHO has more precise data, 3 of the 107 candidates in the clinical phase are being tested for oral administration, 91 will be administered by injection, like those already approved. In terms of dosing regimen, the total breaks down as follows: 15 have a single dose under trial, 70 have a two-dose regimen, and one vaccine candidate has a three-dose regimen. For the remaining 21, WHO does not have more detailed data in this regard.

COVID-19 vaccine: status quo in research
In addition to the already known three technologies of inactivated virus, vector, and RNA, the 291 projects are researching other mechanisms, including vaccines based on protein subunits or on DNA, or with live but highly attenuated and thus harmless viruses.

The advantage of the different vaccine technologies is that they can be used to respond more quickly to a pandemic. If new viruses or further mutations emerge, a more flexible response is possible if individual technologies do not have to be started from scratch but can be based on existing knowledge and only individual factors of a vaccine have to be exchanged. This was also one of the reasons why the first vaccines against COVID-19 were already available in less than a year.

— source: vienna.at/APA/picture: pixabay.com

This post has already been read 25 times!

Leave a Reply

Your email address will not be published. Required fields are marked *